1	TO THE HOUSE OF REPRESENTATIVES:	
2	The Committee on Human Services to which was referred House Bill No.	
3	663 entitled "An act relating to expanding access to contraceptives"	
4	respectfully reports that it has considered the same and recommends that the	
5	bill be amended by striking out all after the enacting clause and inserting in	
6	lieu thereof the following:	
7	Sec. 1. 8 V.S.A. § 4099c is amended to read:	
8	§ 4099c. REPRODUCTIVE HEALTH EQUITY IN HEALTH INSURANCE	
9	COVERAGE	
10	(a) As used in this section, "health insurance plan" means any individual or	
11	group health insurance policy, any hospital or medical service corporation or	
12	health maintenance organization subscriber contract, or any other health	
13	benefit plan offered, issued, or renewed for any person in this State by a health	
14	insurer, as defined by 18 V.S.A. § 9402, or by a pharmacy benefit manager on	
15	behalf of a health insurer. The term shall not include benefit plans providing	
16	coverage for a specific disease or other limited benefit coverage.	
17	(b) A health insurance plan shall provide coverage for outpatient	
18	contraceptive services including sterilizations, and shall provide coverage for	
19	the purchase of all prescription contraceptives and prescription contraceptive	
20	devices approved by the federal Food and Drug Administration, except that a	
21	health insurance plan that does not provide coverage of prescription drugs is	
	VT LEG #346184 v.1	

1	not required to provide coverage of prescription contraceptives and		
2	prescription contraceptive devices. A health insurance plan providing		
3	coverage required under this section shall not establish any rate, term, or		
4	condition that places a greater financial burden on an insured or beneficiary for		
5	access to contraceptive services, prescription contraceptives, and prescription		
6	contraceptive devices than for access to treatment, prescriptions, or devices for		
7	any other health condition.		
8	(c) A health insurance plan shall provide coverage without any deductible,		
9	coinsurance, co-payment, or other cost-sharing requirement for at least one		
10	drug, device, or other product within each method of contraception for		
11	women identified by the U.S. Food and Drug Administration (FDA) and		
11 12	women identified by the U.S. Food and Drug Administration (FDA) and prescribed by an insured's health care provider.		
12	prescribed by an insured's health care provider.		
12 13	prescribed by an insured's health care provider. (1) The coverage provided pursuant to this subsection shall include		
12 13 14	prescribed by an insured's health care provider. (1) The coverage provided pursuant to this subsection shall include patient education and counseling by the patient's health care provider		
12 13 14 15	prescribed by an insured's health care provider.(1) The coverage provided pursuant to this subsection shall includepatient education and counseling by the patient's health care providerregarding the appropriate use of the contraceptive method prescribed.		
12 13 14 15 16	 prescribed by an insured's health care provider. (1) The coverage provided pursuant to this subsection shall include patient education and counseling by the patient's health care provider regarding the appropriate use of the contraceptive method prescribed. (2)(A) If there is a therapeutic equivalent of a drug, device, or other 		
12 13 14 15 16 17	 prescribed by an insured's health care provider. (1) The coverage provided pursuant to this subsection shall include patient education and counseling by the patient's health care provider regarding the appropriate use of the contraceptive method prescribed. (2)(A) If there is a therapeutic equivalent of a drug, device, or other product for an FDA-approved contraceptive method, a health insurance plan 		

1	(B) If an insured's health care provider recommends a particular	
2	service or FDA-approved drug, device, or other product for the insured based	
3	on a determination of medical necessity, the health insurance plan shall defer	
4	to the provider's determination and judgment and shall provide coverage	
5	without cost-sharing for the drug, device, or product prescribed by the provider	
6	for the insured.	
7	(d) A health insurance plan shall provide coverage for voluntary	
8	sterilization procedures for men and women without any deductible,	
9	coinsurance, co-payment, or other cost-sharing requirement, except to the	
10	extent that such coverage would disqualify a high-deductible health plan from	
11	eligibility for a health savings account pursuant to 26 U.S.C. § 223.	
12	(e) A health insurance plan shall provide coverage without any	
13	deductible, coinsurance, co-payment, or other cost-sharing requirement	
14	for clinical services associated with providing the drugs, devices, products,	
15	and procedures covered under this section and related follow-up services,	
16	including management of side effects, counseling for continued adherence,	
17	and device insertion and removal.	
18	(f)(1) A health insurance plan shall provide coverage for a supply of	
19	prescribed contraceptives intended to last over a 12-month duration, which	
20	may be furnished or dispensed all at once or over the course of the 12 months	
21	at the discretion of the health care provider. The health insurance plan shall	
	VT LEG #346184 v.1	

1	reimburse a health care provider or dispensing entity per unit for furnishing or		
2	dispensing a supply of contraceptives intended to last for 12 months.		
3	(2) This subsection shall apply to Medicaid and any other public health		
4	care assistance program offered or administered by the State or by any		
5	subdivision or instrumentality of the State.		
6	(g) Benefits provided to an insured under this section shall be the same for		
7	the insured's covered spouse and other covered dependents.		
8	(h) The coverage requirements of this section shall apply to self-		
9	administered hormonal contraceptives dispensed by a pharmacist to an insured		
10	without a prescription in accordance with 26 V.S.A. § 2024. (from H.752)		
11	Sec. 2. 16 V.S.A. § 132 is added to read:		
12	§ 132. SECONDARY SCHOOLS; PROVISION OF CONTRACEPTIVES		
13	In order to prevent or reduce unintended pregnancies, each school		
14	district shall coordinate with the Department of Health to distribute and		
15	make available to all students in its secondary schools, free of charge,		
16	over-the-counter contraceptive devices and products.		
17	Option #1 (Dept. of Health/Agency of Education – flexible implementation):		
18	In order to prevent or reduce unintended pregnancies and sexually		
19	transmitted diseases, each school district shall make available to all		
20	students in its secondary schools, free of charge, over-the-counter barrier		
21	method contraceptives. School district administrative teams, in		

1	consultation with school district nursing staff, shall determine the best
2	manner in which to make the contraceptives available to students.
3	<i>Option #2 (Dept. of Health/Agency of Education – clear directive):</i>
4	In order to prevent or reduce unintended pregnancies and sexually
5	transmitted diseases, each school district shall make available to all
6	students in grades X through 12, free of charge, condoms and <mark>[other over-</mark>
7	the-counter barrier method contraceptives?]. Condoms shall be placed in
8	locations that are safe and readily accessible to students, including the
9	school nurse's office.
10	Sec. 3. 18 V.S.A. § 12 is added to read:
11	<u>§ 12. PROVISION OF INFORMATION REGARDING</u>
12	<u>CONTRACEPTIVES</u>
13	In order to prevent or reduce unintended pregnancies, the Department
14	<mark>of Health shall coordinate with health care providers, school districts,</mark>
15	public and private colleges and universities, and other stakeholders to
16	<mark>distribute and make available, free of charge, over-the counter</mark>
17	contraceptive devices and products to individuals in a variety of settings
18	<mark>statewide.</mark>
19	In order to prevent or reduce unintended pregnancies and sexually
20	transmitted diseases, the Department of Health, in partnership with
01	

21 health care providers and health insurers, shall communicate to

1	adolescents and other individuals of reproductive age information		
2	regarding contraceptive access and coverage.		
3	Sec. 4. 33 V.S.A. § 4913 is amended to read:		
4	§ 4913. REPORTING CHILD ABUSE AND NEGLECT; REMEDIAL		
5	ACTION		
6	(a) A mandated reporter is any:		
7	* * *		
8	(2) individual who is employed by a school district or an approved or		
9	recognized independent school, or who is contracted and paid by a school		
10	district or an approved or recognized independent school to provide student		
11	services, including any:		
12	(A) school superintendent;		
13	(B) headmaster of an approved or recognized independent school as		
14	defined in 16 V.S.A. § 11;		
15	(C) school teacher;		
16	(D) student teacher;		
17	(E) school librarian;		
18	(F) school principal; and		
19	(G) school guidance counselor;		
20	* * *		

1	(1) A mandated reporter as described in subdivision (a)(2) of this section		
2	shall not be deemed to have violated the requirements of this section solely on		
3	the basis of distributing or making available over-the-counter contraceptive		
4	devices and products to secondary school students in accordance with 16		
5	<u>V.S.A. § 132 or 18 V.S.A. § 12, or both.</u>		
6	Sec. 5. 26 V.S.A. § 2022 is amended to read: (from H.752)		
7	§ 2022. DEFINITIONS		
8	As used in this chapter:		
9	* * *		
10	(15)(A) "Practice of pharmacy" means:		
11	* * *		
12	(vii) optimizing drug therapy through the practice of clinical		
13	pharmacy; and		
14	(viii) dispensing self-administered hormonal contraceptives in		
15	accordance with section 2024 of this chapter; and		
16	(ix) performing or offering to perform those acts, services,		
17	operations, or transactions necessary in the conduct, operation, management,		
18	and control of pharmacy.		
19	* * *		
20	(21) "Self-administered hormonal contraceptive" means a contraceptive		
21	medication or device approved by the U.S. Food and Drug Administration that		
	VT LEG #346184 v.1		

1	prevents pregnancy by using hormones to regulate or prevent ovulation and	
2	that uses an oral, transdermal, vaginal, or depot injection route of	
3	administration.	
4	Sec. 6. 26 V.S.A. § 2024 is added to read: (from H.752)	
5	§ 2024. DISPENSING CONTRACEPTIVES WITHOUT A PRESCRIPTION	
6	(a) A licensed pharmacist who meets the requirements of the rules adopted	
7	by the Board pursuant to this section may dispense self-administered hormonal	
8	contraceptives to a patient without a prescription.	
9	(b) The Board of Pharmacy, in consultation with the Board of Medical	
10	Practice and other interested health professional associations and stakeholders,	
11	shall adopt rules pursuant to 3 V.S.A. chapter 25 establishing the conditions	
12	under which a pharmacist may dispense self-administered hormonal	
13	contraceptives to a patient without a prescription and the standard procedures	
14	that a pharmacist shall use to select the appropriate contraceptive for a patient	
15	or to refer the patient to a primary care provider or reproductive health care	
16	provider for treatment. The Board's rules shall require the pharmacist to:	
17	(1) complete an educational training program accredited by the	
18	Accreditation Council for Pharmacy Education relating to hormonal	
19	contraceptives, unless the pharmacist has already undergone this training as	
20	part of the pharmacist's formal educational program;	

1	(2) comply with the most current U.S. Medical Eligibility Criteria for			
2	Contraceptive Use as adopted by the Centers for Disease Control and			
3	Prevention;			
4	(3) provide a self-screening risk assessment tool that a patient must use			
5	before a pharmacist may dispense hormonal contraceptives to the patient			
6	without a prescription:			
7	(4) follow other standard procedures established by the Board; and			
8	(5) after dispensing hormonal contraceptives to a patient without a			
9	prescription:			
10	(A) refer the patient for additional care to the patient's primary care			
11	provider or reproductive health care provider or, if the patient does not have a			
12	primary care or reproductive health care provider, to a family planning			
13	provider or licensed clinician who provides reproductive health care services;			
14	(B) provide the patient with:			
15	(i) a written record of the contraceptives dispensed; and			
16	(ii) written information about the importance of seeing the			
17	patient's primary care provider or reproductive health care provider to obtain			
18	recommended tests and screenings;			
19	(C) record the dispensing of the contraceptives in any electronic			
20	health record maintained on the patient by the pharmacist; and			

1	(D) provide the patient with a copy of the record of the encounter that			
2	includes the patient's completed self-assessment tool and the contraceptive			
3	dispensed or, if applicable, the basis for not dispensing the contraceptive.			
4	Sec. 7. BOARD OF PHARMACY; RULEMAKING (from H.752)			
5	The Board of Pharmacy, in consultation with the Board of Medical Practice			
6	and other interested health professional associations and stakeholders, shall			
7	adopt rules pursuant to 3 V.S.A. chapter 25 to enable pharmacists to dispense			
8	self-administered hormonal contraceptives to patients without a prescription as			
9	set forth in 26 V.S.A. § 2024, as added by Sec. 2 of this act. The Board shall			
10	proceed expeditiously with the rulemaking process in order to ensure that the			
11	rules will be in effect to enable licensed pharmacists to begin dispensing self-			
12	administered hormonal contraceptives to patients without a prescription on			
13	January 1, 2021.			
14	Sec. 8. EFFECTIVE DATES			
15	(a) Sec. 1 (8 V.S.A. § 4099c) shall take effect on January 1, 2021 and shall			
16	apply to group health insurance plans issued on and after January 1, 2021 on			
17	such date as a health insurer offers, issues, or renews the plan, but in no event			
18	later than January 1, 2022.			
19	(b) Secs. 5 (26 V.S.A. § 2022) and 6 (26 V.S.A. § 2024) shall take effect			
20	<u>on January 1, 2021. (from H.752)</u>			
21	(c) The remainder of this act shall take effect on passage July 1, 2020.			

Page 11 of 11	
---------------	--

1		
2		
3		
4		
5	(Committee vote:)	
6		
7		Representative
8		FOR THE COMMITTEE